poster

Impact of Centanafadine on the ASRS After 6 Weeks of Treatment of ADHD in Adults: A Pooled Analysis of Two Phase 3 Trials

Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...

11/26/2024

Adjunctive Treatment With Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder With Insomnia

Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...

11/26/2024

Guiding antidepressant choice by applying deep learning approaches on individual patient-derived neurons: a window to drug efficacy in each patient

Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...

11/26/2024

Clinical effectiveness and persistence on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup

BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...

11/26/2024

Real-world clinical effectiveness of esketamine nasal spray based on the Montgomery-Asberg Depression Rating Scale (MADRS) among patients with treatment-resistant depression in the United States

BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...

11/26/2024

Response and remission on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup

BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...

11/26/2024

Comparison of Real-world Response and Remission among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation

BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...

11/26/2024

Effect of Centanafadine on AISRS Over 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials

TBD

11/26/2024

MDD Treatment Selection: Online CME Illustrates Best Practices in Discussing Pharmacogenomic Testing with Patients

This study examined whether an online CME clinical demonstration module can improve learners’ self-reported clinical behaviors related to management of MDD, identifying patients who may b...

11/26/2024

Prescription Digital Therapeutics in Psychiatry: Virtual CME Advances Physician Knowledge and Confidence

Background: Digital therapeutic technologies (DTx) are emerging rapidly, and clinicians are challenged to understand their benefits and how they fit into practice. Physicians require educ...

11/26/2024

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia-Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.